142 related articles for article (PubMed ID: 23354033)
41. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.
Bauman G; Belhocine T; Kovacs M; Ward A; Beheshti M; Rachinsky I
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):45-55. PubMed ID: 21844889
[TBL] [Abstract][Full Text] [Related]
42. False-positive result in 18F-fluorocholine PET/CT due to incidental and ectopic parathyroid hyperplasia.
Cazaentre T; Clivaz F; Triponez F
Clin Nucl Med; 2014 Jun; 39(6):e328-30. PubMed ID: 24152627
[TBL] [Abstract][Full Text] [Related]
43. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.
Fartoux L; Balogova S; Nataf V; Kerrou K; Huchet V; Rosmorduc O; Talbot JN
Nucl Med Commun; 2012 Jul; 33(7):757-65. PubMed ID: 22504293
[TBL] [Abstract][Full Text] [Related]
44. Brain metastases in patient with prostate cancer found in 18F-choline PET/CT.
Gizewska A; Witkowska-Patena E; Stembrowicz-Nowakowska Z; Buraczewska A; Dziuk M
Nucl Med Rev Cent East Eur; 2015; 18(1):39-41. PubMed ID: 25633517
[TBL] [Abstract][Full Text] [Related]
45. Hepatic Metastases From Prostatic Adenocarcinoma Without Elevated 18F-Choline Activity.
Dejust S; Messaoud L; Jallerat P; Marical V; Morland D
Clin Nucl Med; 2018 Oct; 43(10):780-781. PubMed ID: 30153155
[TBL] [Abstract][Full Text] [Related]
46. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
Langsteger W; Heinisch M; Fogelman I
Semin Nucl Med; 2006 Jan; 36(1):73-92. PubMed ID: 16356797
[TBL] [Abstract][Full Text] [Related]
47. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
[TBL] [Abstract][Full Text] [Related]
48. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
Beauregard JM; Williams SG; Degrado TR; Roselt P; Hicks RJ
J Med Imaging Radiat Oncol; 2010 Aug; 54(4):325-32. PubMed ID: 20718912
[TBL] [Abstract][Full Text] [Related]
49. 18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study.
Sharma P; Karunanithi S; Chakraborty PS; Kumar R; Seth A; Julka PK; Bal C; Kumar R
Nucl Med Commun; 2014 Dec; 35(12):1247-53. PubMed ID: 25171438
[TBL] [Abstract][Full Text] [Related]
50. (18)F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer.
Calabria F; Chiaravalloti A; Schillaci O
Clin Nucl Med; 2014 Feb; 39(2):122-30. PubMed ID: 24368525
[TBL] [Abstract][Full Text] [Related]
51. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
52. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
53. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
54. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates.
Krause BJ; Souvatzoglou M; Treiber U
Urol Oncol; 2013 May; 31(4):427-35. PubMed ID: 21388835
[TBL] [Abstract][Full Text] [Related]
55. 18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound.
Avery R; Kuo PH
Clin Nucl Med; 2013 Sep; 38(9):746-8. PubMed ID: 23797230
[TBL] [Abstract][Full Text] [Related]
56. Significance of 18F-fluorocholine PET/CT positive pulmonary lesions in prostate cancer patients.
Rager O; Baskin A; Amzalag G; Buchegger F; Miralbell R; Ratib O; Zilli T; Garibotto V
Nuklearmedizin; 2015; 54(5):211-6. PubMed ID: 26213186
[TBL] [Abstract][Full Text] [Related]
57. Penile Metastasis From Prostate Cancer Detected by 18F-Fluorocholine PET/CT.
Bianchi D; Rizzo A; Bonacina M; Zaniboni A; Savelli G
Clin Nucl Med; 2021 Jan; 46(1):e38-e39. PubMed ID: 32956108
[TBL] [Abstract][Full Text] [Related]
58. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
[TBL] [Abstract][Full Text] [Related]
59. Fluorocholine PET/CT in patients with prostate cancer: initial experience.
Schmid DT; John H; Zweifel R; Cservenyak T; Westera G; Goerres GW; von Schulthess GK; Hany TF
Radiology; 2005 May; 235(2):623-8. PubMed ID: 15858102
[TBL] [Abstract][Full Text] [Related]
60. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin.
Blodgett TM; Ames JT; Torok FS; McCook BM; Meltzer CC
Clin Nucl Med; 2004 Mar; 29(3):161-3. PubMed ID: 15162984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
